rna-vaccines
(2)
Tiba Biotech
Tiba Biotech is a Cambridge, Massachusetts preclinical biotech spun out of MIT and the Whitehead Institute that is building a new generation of RNA vaccines and therapeutics. Its RNABL platform swaps the fragile lipid nanoparticles behind first-generation mRNA shots for fully synthetic, biodegradable dendrimer nanoparticles that carry larger RNA payloads with less toxicity and gentler cold-chain demands. The company is applying the technology across human vaccines, cancer immunotherapy, gene editing delivery, and animal health, backed by CEPI, BARDA, the NIH, and the NCI.
Karl Ruping
Karl Ruping is the founder and CEO of Tiba Biotech, a Cambridge, Massachusetts company developing biodegradable nanoparticle delivery systems for RNA vaccines and therapeutics. He also runs incTANK Ventures, a seed fund spun out of MIT and Boston-area research labs, and sits at Harvard's Asia Center as an associate working on international patent policy. Lawyer, computational scientist, financier, and operator wrapped into one resume.